CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 276 enrolled
Drug / intervention
Perfusion MRIdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01600105
NCT01600105Phase 4Completed
CompareCT.gov

Prospective Detection of Liver Fibrosis With MRI Compared to Fibroscan and Blood Tests

Bachir Taouli·interventional·Posted May 16, 2012·Updated Feb 7, 2020

In Brief

A Phase 4 clinical trial evaluating Perfusion MRI for Chronic Liver Disease. Completed, enrolled 276 participants across 1 site.

Detailed Summary

Patients with chronic liver disease are at high risk of developing liver scarring (fibrosis), with ultimate risks of cirrhosis and liver cancer that may require liver transplant. The investigators would like to develop non invasive advanced Magnetic Resonance Imaging (MRI) techniques (MR diffusion, perfusion and elastography) to assess the degree of liver damage in patients with chronic liver disease. These techniques combined could reach high diagnostic performance for detection of liver fibrosis; and could decrease the number of liver biopsies, which have risks and sample only a small portion of the liver.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Liver Disease
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 16, 2012
Enrollment StartOct 1, 2010
Primary CompletionJul 31, 2017
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 14.1 years ago

Interventions

Perfusion MRIdrug

1\) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.